Quarterly update in second quarter of 2026

JUMP+ Plan

Year 2026 - 2028

JSP PHARMACEUTICAL MANUFACTURING (THAILAND) PUBLIC COMPANY LIMITED

(JSP)

at 30 June 2026

This report was disseminated on 25/08/2026

Table of Contents

JSP PHARMACEUTICAL MANUFACTURING (THAILAND) PUBLIC COMPANY LIMITED

mai

Consumer Products

CG Report :

SET ESG Ratings: -

Anti-Corruption Certification (CAC): -

Business Type

Develop, manufacture, and sell modern medicine, traditional medicine, herbal product, dietary supplement, medical supply, and cleaning alcohol under client's trademark and the Company's trademark.

Financial Statement

Year	2025	2024	2023	2022
Income Statement (MB)				
Revenues	1,042.68	845.93	594.36	436.45
Expenses	924.83	859.57	584.30	450.90
Net Profit	67.87	4.52	-1.27	-17.48
Balance Sheet (MB)				
Assets	1,463.56	1,326.65	1,335.67	1,222.40
Liabilities	536.56	444.13	405.17	280.37
Shareholders' Equity	908.61	858.00	870.06	942.02
Cash Flow (MB)				
Operating	130.93	132.12	40.35	-5.15
Investing	-277.38	-56.64	-202.49	-469.22
Financing	164.99	-66.64	82.60	-53.74
Financial Ratio				
EPS (Baht)	0.14	0.01	-0.01	-0.04
GP Margin (%)	40.14	36.99	25.10	28.62
NP Margin (%)	4.33	-3.92	4.75	-4.01
D/E Ratio (Times)	0.58	0.50	0.44	0.30
ROE (%)	7.68	0.52	-0.14	-1.83
ROA (%)	8.21	-1.26	3.95	-1.14

JUMP+ Plan

Business Plan

Target in 2028

Operating revenue	**1,540.00** Million Baht

Strategic Plan	Growth	Profitability & Efficiency	Stability
1. Strategic Plan 1 : Elevate Own-Brand	✓		
2. Strategic Plan 2 : Growing OEM and Beyond	✓		
3. Strategic Plan 3 : International Expansion	✓		
4. Strategic Plan 4 : Business Expansion Along the Value Chain	✓	✓	
5. Strategic Plan 5 : Capture Opportunity Through Investments & Partnerships	✓	✓	
6. Strategic Plan 6 : Operational Efficiency & Cost Optimization		✓	

Governance Plan

1. Enhancing the competency and performance of the board of directors
2. Enhancing anti-corruption and fraud prevention efforts
3. Formulation of a succession plan for the CEO, executive management, and critical roles
4. Strengthening emerging risk oversight practices

Climate Action Plan

1. Greenhouse gas inventory (GHG) plan

Quarterly update

Section 1

Business Plan

Quarterly update : Section 1 Business Plan

Target in 2028

Title	Target	Actual Result	
	2028	2025	6M/2026
Operating revenue (Million Baht)	1,540.00	1010.22	437.89

The Company has set a revenue growth target for 2028 at THB 1,540 million, with a compound annual growth rate (CAGR) of 15.1% from the 2025 revenue base. The Company aims to drive performance by elevating its own-brand business, growing its OEM business and beyond, expanding in international markets, strengthening its business along the value chain, capturing opportunities through investments and strategic partnerships, and enhancing operational efficiency alongside cost optimization, in order to support sustainable growth and enhance long-term profitability. Over the next three years, the Company will focus on elevating own-brand business through a comprehensive marketing strategy. This will include evidence-based marketing to build confidence in its products and broaden brand awareness across multiple channels, including advertising media, health store channels, TV home shopping, and collaborations with influencers, particularly those with genuine health expertise, to improve consumer reach and support purchase decisions. At the same time, the Company will further strengthen its online channels by expanding sales through platforms such as TikTok Shop, while building communities to enhance brand awareness and broaden access to more diverse target customer segments. In terms of product development, the Company will continue to prioritize ongoing innovation to strengthen its core products, while pursuing licenses for new products across pharmaceuticals, dietary supplements, herbal products, and cosmetics in order to expand into high-potential product categories. In addition, the Company plans to enter new markets such as pet and livestock products, while also leveraging innovation to develop agricultural products from residual materials generated in Suphap Osod production process, thereby enhancing resource utilization and creating new business opportunities in the future. In its contract manufacturing business, the Company will continue to grow OEM business and beyond by maintaining its major OEM customer base while expanding its portfolio of new OEM customers in order to diversify revenue sources and reduce concentration risk. The Company will also enhance its research and development (R&D) capabilities to develop innovative new products, while strengthening its expertise in pharmaceutical and supplement formulations as well as production technology. In parallel, the Company will further develop its end-to-end service model, covering formulation design, research and development, pilot production, and product registration, in order to improve operational efficiency and deliver a more comprehensive customer service experience. In addition, the Company plans for international expansion by recruiting and establishing dedicated teams to support systematic growth in overseas markets. The Company will also conduct market studies and develop appropriate market entry models for each target country, with a focus on high-potential markets such as China, India, Vietnam, and other ASEAN countries, while building partnerships with local distributors and business partners to strengthen distribution channels and improve long-term market access. Beyond growth from its core businesses, the Company will also pursue business expansion along the value chain in order to create new revenue streams and enhance overall business value through the development of its subsidiaries and related businesses. This includes expanding Caresutic's partner network, enhancing CDIP's R&D capabilities to identify new market opportunities, developing the capabilities of public-sector personnel, and exploring the feasibility of listing on the LiVEx exchange to support future fundraising and business expansion. At the same time, Grace Water Med will focus on improving production efficiency and quality control, exploring new business opportunities along the value chain, and strengthening its trading business for dialysis-related equipment and products, as well as expanding its network of dialysis clinic partners, in order to support the continued growth of its health-related businesses. In addition to organic growth, the company will capture opportunities through investments & partnerships. The Company will evaluate potential investments in healthcare-related businesses that are aligned with its mission and vision in order to support entry into new markets, strengthen its business portfolio, and create long-term growth opportunities through collaboration with high-potential strategic partners. To further enhance competitiveness and profitability on an ongoing basis, the Company will continue to focus on improving operational efficiency and cost optimization through production process improvements, automation, raw material and energy cost reductions, capacity utilization enhancement, and the application of innovation and technology to support cost reduction and operational improvement. These initiatives will serve as key factors in supporting the Company's sustainable long-term growth.

Growth plan/Increase business value

Strategic Plan 1 : Elevate Own-Brand

1. **Strengthening Core product through Marketing Excellence**
   - Implement evidence-based marketing by using data to build product credibility and consumer confidence.
   - Execute broad-based marketing activities to enhance brand awareness, including strengthening sales through billboard advertising and health store channels.
   - Strengthen the TV home shopping channel.
   - Collaborate other brands to broaden access to more diverse target customer groups.
   - Utilize health-focused influencers with authentic expertise to accelerate sales conversion and expand reach across a wider range of target audiences.
2. **Accelerating Online Channels**
   - Expand online sales channels, such as TikTok Shop, while building online communities to promote products and enhance customer reach.
3. **Continuous Innovation and Obtaining Regulatory Approvals for New Product**
   - Strengthen core products through R&D.
   - Obtain Regulatory Approvals for New Product Lines in the pharmaceutical, dietary supplement, herbal, and cosmetic categories, such as dietary supplements for dialysis patients and soft gelatin products.
   - Enter new markets, including pet and livestock products, such as Andrographis paniculata products for pets and livestock.
   - Apply innovation to develop agricultural products from residual materials generated in Suphap Osod production process, such as black sesame.

Targets

- **Corporate Financial Targets**

Title	Target			Actual Result	
	2026	2027	2028	2025	6M/2026
Revenue Growth (%) YoY Growth Rate	15.0	15.0	15.0	37.32	-28.01

Progress description

Total revenue growth from Own-Brand business for 6M/2026 was 28.01% decreased from 6M/2025 due to economic sluggish and that pressured consumers' spending. However, the Company adapted to current situation by presenting new products to customers and increase channels of distribution via omni channel.

Strategic Initiative

Strategic Initiative : The Company aims to strengthen its own-brand products as a key high-margin revenue driver by developing differentiated, high-quality products that meet consumer needs in the health and beauty segments. At the same time, the Company will enhance brand credibility and expand both online and offline marketing channels in order to increase brand awareness, broaden its customer base, and support the Company's sustainable long-term growth.

Status ● On track

Year	Expected Outcomes	Actual Result
2026	• Revenue from the Own-Brand business achieves targeted growth, particularly in the Product Champion category. • Brand awareness and credibility increase significantly through evidence-based marketing and the use of health experts as brand advocates. • Online distribution channels and TV home shopping begin to generate recurring sales and continuously expand the new customer base.	• The Company has created brand awareness continually through core medias which could assist product advertising. In addition, the Company expanded channels of distribution through omni channel to attract new customers. • The Company is considering expand product portfolio in personal care products (FMCG)

Strategic Plan 2 : Growing OEM and Beyond

1. **Retaining and Capturing New Major OEM Customers**
   - Sustain strong growth from key OEM customers.
   - Expand the base of new OEM customers to increase revenue sources and reduce dependency on existing customers.
2. **Consistent Research and Development (R&D) for New Product Innovation**
   - Develop new innovative products.
   - Enhance capabilities in pharmaceutical formulations, dietary supplement formulations, and production technology.
3. **Implementing Integrated Operating Systems to Enhance Customer Service**
   - Provide end-to-end services covering formulation design, product research and development, pilot production, and product registration in order to enhance the customer service experience.

Targets

- **Corporate Financial Targets**

Title	Target			Actual Result	
	2026	2027	2028	2025	6M/2026
Revenue Growth (%) YoY Growth Rate	15.0	15.0	15.0	37.04	-15.04

Progress description

The Company had revenue growth from OEM business for 6M2026 15.04% lower than 6M/2025. This was because geopolitical unstabilities had negative impact to supply materials on time. However, the Company still retained good relationships with key customers and offered new products to those group of customers.

Strategic Initiative

Strategic Initiative : The Company aims to continuously expand its OEM business by maintaining its core customer base while capturing new customers. This will be driven by strengthening research and development capabilities, enhancing manufacturing standards, and developing new products that align with market demand. Expanding the OEM portfolio will help increase revenue, reduce the risk of reliance on any single customer, and strengthen the stability of the Company's revenue structure, while also creating opportunities to extend into new markets and product categories in the future.

Status ● On track

Year	Expected Outcomes	Actual Result
2026	• Revenue from major OEM customers grows steadily through the retention of existing customers and the continued increase in production orders. • The Company begins to expand its new customer base in the health and nutrition product segments, helping to diversify risk from dependence on existing customers. • Research and development (R&D) capabilities and end-to-end service offerings begin to create differentiation and improve the Company's ability to secure new customers.	• The Company had continually orders from key customers. • The Company offered new form of product to OEM business i.e. soft gelatin conventional medicine

Strategic Plan 3 : International Expansion

1. **Expanding Teams to Support Overseas Growth**
   - Recruit and establish new teams to further support operations in international markets.
2. **Exploring New Markets and Models of Entry with Strategic Partners**
   - Identify high-potential target countries, including China, India, Vietnam, and ASEAN markets, and build partnerships with distributors and local business partners to strengthen distribution channels and improve access to target markets.

Targets

- **Corporate Financial Targets**

Title	Target			Actual Result	
	2026	2027	2028	2025	6M/2026
Revenue Growth (%) YoY Growth Rate	15.0	15.0	15.0	37.04	-15.04

Strategic Initiative

Strategic Initiative : The Company aims to expand into international markets by enhancing its export capabilities, building strategic partnerships in target countries, and developing products that comply with international standards and regulations. The Company will focus on high-potential markets in order to create new revenue streams and diversify risk away from the domestic market. International expansion will serve as a key growth engine in increasing business scale, strengthening competitiveness, and elevating the Company's position as a regional player in the long term.

Status ● On track

Year	Expected Outcomes	Actual Result
2026	• Export revenue begins to grow significantly from initial entry into target markets and the establishment of overseas partner networks. • The organizational structure and international go-to-market processes begin to take shape, providing a systematic foundation for further market expansion. • The Company has core products that have been reformulated and adapted to comply with the regulations and standards of target countries, while beginning to establish an overseas customer base.	• The Company has started registering product license abroad to support target group of customers • The Company increased channels of distribution in high potential foreign countries

Strategic Plan 4 : Business Expansion Along the Value Chain

1. **Caresutic**
   - Expand the partner network to support business growth and the development of new products.
2. **CDIP**
   - Strengthen research and development (R&D) capabilities to identify new market opportunities.
   - Provide training and capability development for public-sector personnel.
   - Explore the opportunity to list on the LiVEx exchange in order to raise funds for business expansion and product development.
   - Leverage existing assets, such as vending machine, to create new revenue streams.
3. **Grace Water Med (GWM)**
   - Improve production efficiency and quality control processes.
   - Explore new business expansion opportunities along the value chain to create new revenue streams and add value to the core business.
   - Strengthen the trading business for dialysis equipment and products under Waree Medical, while expanding the partner network of dialysis clinics under Waree Medical.

Targets

- **Corporate Financial Targets**

Title	Target			Actual Result	
	2026	2027	2028	2025	6M/2026
Revenue Growth (%) YoY Growth Rate	15.0	15.0	15.0	23.26	-10.18
Gross Profit Margin (%)	41.6	41.9	42.1	40.14	36.94

Strategic Initiative

Strategic Initiative : The Company aims to systematically develop and expand the roles of its subsidiaries in order to enhance the completeness of its business portfolio across the entire value chain, from upstream to downstream. This will be achieved by building on the specialized strengths of each subsidiary in research and development, training and capability development, specialized services, and medical-related businesses, while supporting growth through investment, fundraising, and the expansion of business partnerships. These efforts are intended to create new revenue streams, add value to the core business, and strengthen the long-term competitiveness of the Group.

Status ● On track

Year	Expected Outcomes	Actual Result
2026	• Revenue from subsidiaries begins to grow significantly through the expansion of existing businesses and the addition of specialized services in the health and medical sectors. • The structure of the Group's affiliated businesses becomes clearer, creating synergies among manufacturing, research, and healthcare service businesses, which help enhance the value of the core business. • Investment projects and new business development initiatives along the value chain begin to enter the revenue-generating stage, laying the foundation for long-term growth.	• The Company expanded business to pet care products • The Company is comtemplating opportunities in dialysis centre, which will be operated by an affiliated company • The Company developed a synergy with an affiliated company to offer consumer staples for kidney patients

Strategic Plan 5 : Capture Opportunity Through Investments & Partnerships

1. **Strategic Partnership**
   - Explore the feasibility of investing in healthcare-related businesses that are aligned with the Company's mission and vision.
   - Enter new markets and strengthen the business portfolio for long-term growth.

Targets

- **Corporate Financial Targets**

Title	Target			Actual Result	
	2026	2027	2028	2025	6M/2026
Revenue Growth (%) YoY Growth Rate	15.0	15.0	15.0	23.26	-10.18
Gross Profit Margin (%)	41.6	41.9	42.1	40.14	36.94

Strategic Initiative

Strategic Initiative : The Company aims to pursue strategic investments to accelerate long-term business growth through potential partnership collaborations in high-potential businesses, access to new markets, and the enhancement of technological and innovation capabilities. Such investments will serve as an important tool in expanding the business portfolio, increasing strategic flexibility, and continuously creating added value for shareholders.

Status ● On track

Year	Expected Outcomes	Actual Result
2026	• The Company restructures its organization through the establishment of a Wellness Venture Capital unit.	The Company is establishing Wellness Venture Capital

Strategic Plan 6 : Operational Efficiency & Cost Optimization

1. Enhancing Production Efficiency and Cost Management

- Improve production processes and automation systems.
- Reduce raw material and energy costs.
- Increase capacity utilization efficiency.
- Apply innovative technologies to reduce costs and improve efficiency.

Targets

- **Corporate Financial Targets**

Title	Target			Actual Result	
	2026	2027	2028	2025	6M/2026
Gross Profit Margin (%)	41.6	41.9	42.1	40.14	36.94

Strategic Initiative

Strategic Initiative : The Company aims to enhance operational efficiency and cost management through improvements in production processes, the adoption of automation systems and digital technologies, the reduction of raw material and energy costs, and the optimization of capacity utilization. These efforts are intended to strengthen profitability, support business growth, and improve the Company’s long-term competitiveness.

Status ● On track

Year	Expected Outcomes	Actual Result
2026	• Production and energy cost structures begin to decline in a tangible manner through process improvements and the implementation of automation in key production lines. • Capacity utilization efficiency improves, resulting in lower unit costs and a continued improvement in gross profit margin. • Quality control systems and production process management become more standardized, reducing defect rates and losses in the production process.	• The Company improved production efficiency by using machinery to reduce production waste. • The COmpany is submitting investment grant from the Board of Investment of Thailand (BOI)

Quarterly update

Section 2

Governance Plan

Quarterly update : Section 2 Governance Plan

Board Structure and Qualifications

Enhancing the competency and performance of the board of directors

Year 2026: Review the necessary skills of directors for the company's operations, survey directors' skills and prepare a Board Skill Matrix, and set targets for the proportion of directors with sufficient knowledge in each skill area.

Year 2027: Promote the organization of training for directors on topics beneficial to the company's business operations, which may be conducted as internal training or received from external organizations.

Year 2028: Achieve a proportion of directors with knowledge in at least 5 specified skill areas.

Targets

Title	Target			Actual Result	
	2026	2027	2028	Before Project Participation	6M/2026
The company engages external consultants to support the development of the Board's evaluation framework and to provide recommendations for the Board’s performance assessment	In Progress	In Progress	Success	Not Started	Not Started
Define the necessary skills of directors for the company's operations.	Completed	Completed	Completed	-	The Company has been approved from the Board of Directors for necessary skills of directors
Assess director skills and prepare a Board Skill Matrix	Completed	Completed	Completed	-	The Company is surveying board skill for the year 2026
Set targets for the proportion of directors with sufficient knowledge in each skill area.	In progress	Completed	Completed	-	The Company is considering proportion of directors with sufficient knowledge in each skill area
At least 75% of the total number of directors received training during the year.	In progress	In progress	Completed	-	The Company is operating training to directors

Strategic Initiative

Strategic Initiative : Develop directors' knowledge in alignment with the company's strategy and operations, by specifying the target skills directors should possess, and the proportion of individuals possessing the defined skills, with public disclosure.

Status ● On track

Year	Expected Outcomes	Actual Result
2026	• Define the essential skills for directors to possess to support the achievement of the company's strategic objectives. • Set the target proportion of directors with essential skills and knowledge for the company's operations.	• The Company set aside essential board's skills to support the Company's business. The skills were approved by the Board of Directors • The Company is considering targeted proportion of directos with essential skills for the Company's business operations

Accountability and Transparency Governance

Enhancing anti-corruption and fraud prevention efforts

The company aims to operate its management to combat corruption by implementing the anti-corruption policy across all departments within the organization, with activities including training for directors, executives, and employees, communication with customers, suppliers, and stakeholders, and reviewing whistleblower channels.

Year 2026: Declared intention to join the Thai Private Sector Collective Action Against Corruption (CAC) and reviewed internal control systems to comply with assessment criteria.

Year 2028: Achieved CAC Certified membership status.

Targets

Title	Target			Actual Result	
	2026	2027	2028	Before Project Participation	6M/2026
The company has established an anti-corruption policy and practices.	Success	Success	Success	In Progress	In Progress
An anti-corruption and anti-bribery policy has been developed to comprehensively cover the organization's business operations,formally approved by the Board of Directors,and supported by clear and practical implementation guidelines	-	-	-	Complete	Success
The company conducts regular monitoring and evaluation of compliance with its anti-corruption and anti-bribery policy and procedures. Audit results are reported by internal auditors to the Board of Directors at least annually. In the event of any violations,corrective actions and preventive measures are clearly defined to prevent recurrence	Success	Success	Success	Not Started	In Progress
The company conducts an annual review of its anti-	-	-	-	Complete	Success

Title	Target			Actual Result	
	2026	2027	2028	Before Project Participation	6M/2026
corruption and anti-bribery policy and practices with the Board of Directors					
Achieve CAC certification from the Thai Institute of Directors (Thai IOD)	Signatory	In the process of applying for certification.	Certified	Not Started	Not Started
Implement and verify that all critical Tier 1 business partners have anti-corruption policies,and ensure that the company actively monitors and assesses business partners' adherence to these policies	In progress	In progress	Completed	-	The Company is considering measures and monitoring activities for Critical Tier 1 business partners to have anti-corruption policies in place

Strategic Initiative

Strategic Initiative : Partner Upgrading Project, which promotes critical Tier 1 partners directly engaged with the company to establish anti-corruption policies, and continuously monitors and evaluates their performance to enhance transparency and good governance in procurement.

Status ● On track

Year	Expected Outcomes	Actual Result
2026	• Establish criteria and compile a list of critical suppliers (Critical Tier 1) • Communicate anti-corruption to business partners and stakeholders • At least 50% of key partners have signed an acknowledgement of the Partner Code of Conduct policy.	• The Company is setting aside criteria for listing Critical Tier 1 suppliers • The Company is communicating directly with suppliers about anti-corruption policy • The Company has communicated with stakeholders in relation anti-corruption via website

Governance of Risk and Management Compliance

Formulation of a succession plan for the CEO, executive management, and critical roles

2026: Identify all critical organizational positions, covering both technical and administrative roles, and assess the additional skills required for successor development (Successor Skill Gap Analysis).

2027: Develop successors' skills according to job functions and implement systematic leadership potential development (Structured Leadership Acceleration Phase).

2028: Concretely assess the readiness of successors.

Targets

Title	Target			Actual Result	
	2026	2027	2028	Before Project Participation	6M/2026
The company has established a succession plan for the President & CEO,senior executives,and key position holders.	In Progress	Success	Success	In Progress	In Progress
Risk assessment and identification of critical roles to categorize and prioritize positions requiring succession plans.	Success	Success	Success	In Progress	Success
Define core qualifications and competencies by regularly reviewing and updating job descriptions to ensure clarity and relevance,and specifying essential competencies for each position.	Success	Success	Success	Not Started	Success
Identification and assessment of high-potential employees for future key roles.	In Progress	Success	Success	In Progress	In Progress
Development of Individual Development Plans	In Progress	Success	Success	In Progress	In Progress
Monitor IDP progress and evaluate the overall effectiveness of the succession plan,ensuring key role incumbents participate in and complete essential training and skill development.	In Progress	Success	Success	In Progress	In Progress
Effectively communicate the value of the succession plan to employees and encourage a culture of continuous learning across the company.	In Progress	Success	Success	In Progress	In Progress
Expand the implementation of the Succession Plan to cover director-level positions and positions critical to the organization.	In progress	In progress	Completed	-	The Company is now considering clear determin ations about characteristics and

Title	Target			Actual Result	
	2026	2027	2028	Before Project Participation	6M/2026
					expectations over targeted positions

Strategic Initiative

Strategic Initiative : Establish a taskforce to identify key positions and develop Individual Development Plans (IDPs) for succession candidates.

Status ● On track

Year	Expected Outcomes	Actual Result
2026	• The company identifies critical positions requiring clear succession planning and maintains a preliminary list of successors for systematic development.	• The Company has determined critical positions and preliminary list of successors

Strengthening emerging risk oversight practices

Year 2027: Integrate the assessment of emerging risks into the corporate strategic planning process, along with identifying a risk mitigation plan (Mitigation Plan) and assessing damages using Scenario Analysis

Year 2028: Prepare for the disclosure of sustainability risk information according to international standards such as IFRSS2

Targets

Title	Target			Actual Result	
	2026	2027	2028	Before Project Participation	6M/2026
The company has established policies and guidelines for managing emerging risks.	In Progress	Success	Success	Not Started	In Progress
Conduct an analysis to identify and assess a minimum of three emerging risks with potential business impact.	In Progress	Success	Success	Not Started	Not Started
Each emerging risk is accompanied by scenario analysis and corresponding mitigation plans	In Progress	Success	Success	Not Started	Not Started
Engagement of senior management in the tracking and decision processes related to emerging risks.	In Progress	Success	Success	Not Started	Not Started
Develop an emerging risk monitoring and reporting system (Emerging Risk Monitoring System)	In progress	Completed	Completed	-	Not Started

Strategic Initiative

Strategic Initiative : Establish a special task force (Taskforce) to monitor global megatrends and organize foresight thinking (Foresight Thinking) workshops for executives and employees at manager level and above.

Status On track

Year	Expected Outcomes	Actual Result
2026	• The company has an effective alert system, which is regularly monitored, and identifies new threats that may impact the company's business.	• The Company is considering set up taskforce to analyse contingent risks

Quarterly update

Section 3

Climate Plan

Quarterly update : Section 3 Climate Plan

Greenhouse gas inventory (GHG) plan

Year 2027: Completion of greenhouse gas inventory.

Targets

Title	Target			Actual Result
	2026	2027	2028	6M/2026
GHG inventory report, GHG verification and disclosure (specific to Scope 1 and Scope 2 emissions)	In Progress	Success	Success	In Progress

Strategic Initiative

Strategic Initiative : Develop and implement plans to reduce greenhouse gas emissions

Status ● On track

Year	Expected Outcomes	Actual Result
2026	• Increase the use of clean energy in processes, such as Solar Cells.	• The Company is contemplating to use more solar cell in Bangkok plant

Quarterly update

Attachment

Quarterly update : Attachment

JUMP+ Plan

URL Link to the Document : https://jumpplusmedia-setlink.setgroup.or.th/planSubmission/JSP1_JUMP%2B_Plan_Year_2026-2028_EN.pdf